Skip to main content

Conmed Aktie - Fundamentalanalyse - Dividendenrendite KGV

Conmed (ISIN: US2074101013, WKN: 886793) Kursdatum: 22.11.2017 Kurs: 53,180 USD
Beschreibung Daten
Symbol CNMD
Marktkapitalisierung 1.487.125.504,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Gesundheitswesen
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 2001-09-10 - 3:2 | 2001-01-17 - 10:7 |
Internet www.conmed.com
Letztes Bilanz Update 27.02.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 22.11.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
63,37 38,91 1,50% 1,09 43,69 102,27 1,95 2,56

Firmenbeschreibung

Selected Quarterly Financial Data (Unaudited)Selected quarterly financial data for 2015 and 2014 are as follows: Three Months Ended March June September December2015       Net sales$177,940 $181,027 $169,184 $191,017Gross profit92,282 93,498 93,546 102,376Net income6,312 7,461 8,873 7,852EPS:       Basic$.23 $.27 $.32 $.28Diluted.23 .27 .32 .28 Three Months Ended March June September December2014       Net sales$181,941 $188,150 $174,961 $195,003Gross profit102,582 101,028 96,414 104,033Net income8,626 10,255 1,972 11,339EPS:       Basic$.32 $.38 $.07 $.41Diluted.31 .37 .07 .41Items Included In Selected Quarterly Financial Data:2015 First QuarterDuring the first quarter of 2015, we incurred $2.3 million in costs associated with the consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities. These costs were charged to cost of sales and include severance and other charges associated with the consolidation – see Note 11.During the first quarter of 2015, we recorded a charge of $6.2 million to selling and administrative expense related to the restructuring of certain selling and administrative functions which includes severance costs and other related costs - see Note 11.Second QuarterDuring the second quarter of 2015, we incurred $1.5 million in costs associated with the consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities. These costs were charged to cost of sales and include severance and other charges associated with the consolidation – see Note 11.During the second quarter of 2015, we recorded a charge of $2.2 million to selling and administrative expense related to the restructuring of certain selling and administrative functions which includes severance costs and other related costs - see Note 11.Third QuarterDuring the third quarter of 2015, we incurred $1.3 million in costs associated with the consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities. These costs were charged to cost of sales and include severance and other charges associated with the consolidation – see Note 11.During the third quarter of 2015, we recorded a charge of $1.1 million to selling and administrative expense related to the restructuring of certain selling and administrative functions which includes severance costs and other related costs - see Note 11.Fourth QuarterDuring the fourth quarter of 2015, we incurred $2.8 million in costs associated with the consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities. These costs were charged to cost of sales – see Note 11.During the fourth quarter of 2015, we recorded a charge of $4.3 million to selling and administrative expense related to the restructuring of certain selling and administrative functions which includes severance costs and other related costs - see Note 11.During the fourth quarter of 2015, we recorded a charge of $2.1 million to selling and administrative expense associated with the purchase of SurgiQuest, Inc and other acquisitions. - see Note 11 and Note 15.2014 First QuarterDuring the first quarter of 2014, we incurred $0.9 million in costs associated with the moving of additional product lines to our manufacturing facility in Chihuahua, Mexico; consolidation of our Finland operations into our Largo, Florida and Utica, New York manufacturing facilities; consolidation of our Westborough, Massachusetts operations into our Largo, Florida and Chihuahua, Mexico manufacturing facilities and the consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities. These costs were charged to cost of sales – see Note 11.During the first quarter of 2014, we recorded a charge of $0.7 million to selling and administrative expense related to the restructuring of certain administrative functions - see Note 11.    During the first quarter of 2014, we recorded a charge of $1.9 million to selling and administrative expense related to legal fees associated with a patent infringement claim, including $0.9 million in settlement costs - see Note 11. During the first quarter of 2014, we recorded a charge of $0.6 million in selling and administrative expense for professional fees associated with shareholder activism - see Note 11.    In New York State, corporate tax reform enacted in March 2014 changed the tax rate of a manufacturing company such as CONMED to essentially 0%. Previously recorded New York State net deferred tax assets of $2.3 million have been written off as a non-cash charge to income tax expense - see Note 6.    Second QuarterDuring the second quarter of 2014, we incurred $1.4 million in costs associated with the moving of additional product lines to our manufacturing facility in Chihuahua, Mexico and the consolidation of our Centennial, Colorado manufacturing o

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.conmed.com